← Eichor
Condition: Resectable Pancreatic Ductal Adenocarcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Resectable Pancreatic Ductal Adenocarcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 1 · 6 location(s) · PanTher Therapeutics · NCT06673017A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07671339Targeted Pathway Inhibition in Patients With Pancreatic Cancer
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT04005690Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
Phase N/A · 1 location(s) · Emory University · NCT06595160Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal
Phase 2 · 1 location(s) · Mayo Clinic · NCT05518903Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NA · 1 location(s) · British Columbia Cancer Agency · NCT06574620Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreat
Phase 1/Phase 2 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT06782932NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06821997AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Phase N/A · 2 location(s) · Roswell Park Cancer Institute · NCT06320717Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Phase 1 · 2 location(s) · Washington University School of Medicine · NCT06141031PULSAR in Systemic Therapy for Pancreatic Cancer
Phase 2 · 1 location(s) · Samsung Medical Center · NCT07269626Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable
Phase 1/Phase 2 · 1 location(s) · Jonsson Comprehensive Cancer Center · NCT05688215A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05851924Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Phase 3 · 1 location(s) · GC Cell Corporation · NCT04969731Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable
Phase 2 · 1 location(s) · Emory University · NCT06423326Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 3 · 43 location(s) · Revolution Medicines, Inc. · NCT07252232Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
Phase 2 · 3 location(s) · Baylor College of Medicine · NCT05132504French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Phase N/A · 1 location(s) · University Hospital, Montpellier · NCT06287749Durvalumab and Oleclumab in Resectable PDAC
Phase 2 · 1 location(s) · University Health Network, Toronto · NCT06060405A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Phase 1 · 3 location(s) · Astellas Pharma Global Development, Inc. · NCT07024615Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
Phase 1 · 1 location(s) · University of California, San Diego · NCT06639724Pancreatic Cancer Detection Consortium
Phase N/A · 11 location(s) · City of Hope Medical Center · NCT06388967Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Phase 2 · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT03977233
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.